Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.54 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | AMY2A | P04746 | 1/20 | 0.44 |
| ▸ | GJA1 | P17302 | 1/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12901988 | 1.00 | TYR (0.56) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL12604931 | 1.00 | TYR (0.56) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL12563491 | 1.00 | TYR (0.56) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL12563490 | 1.00 | TYR (0.56) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL17341181 | 0.92 | TYR (0.48) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL21132597 | 0.92 | MEN1 (0.50) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL10047647 | 0.92 | TYR (0.48) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL15095371 | 0.92 | TYR (0.49) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL15095372 | 0.92 | TYR (0.49) | TYRLGALS8LGALS3LGALS4MEN1 | |
| SCHEMBL13026650 | 0.90 | TYR (0.48) | TYRLGALS8LGALS3LGALS4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | TYR 3651/4885LGALS8 971/4885LGALS3 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.